Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 13;170(22):2035-6.
doi: 10.1001/archinternmed.2010.461.

Persistence of cardiovascular risk after rofecoxib discontinuation

Joseph S Ross, David Madigan, Marvin A Konstam, David S Egilman, Harlan M Krumholz

Persistence of cardiovascular risk after rofecoxib discontinuation

Joseph S Ross et al. Arch Intern Med. .

Erratum in

  • Arch Intern Med. 2011 Feb 28;171(4):305
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Investigator-reported cardiovascular thrombotic events and all-cause deaths observed during off-drug follow-up within study 078.
See this image and copyright information in PMC

References

    1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102. - PubMed
    1. Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372(9651):1756–1764. - PubMed
    1. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30(6):1204–1215. - PubMed
    1. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med. 2009;169(21):1976–1985. - PMC - PubMed
    1. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008;299(15):1813–1817. - PubMed

Publication types

MeSH terms